Sen­a­tors want to know more on why No­vo is dis­con­tin­u­ing its in­sulin Lev­emir

No­vo Nordisk de­cid­ed to dis­con­tin­ue its long-act­ing in­sulin Lev­emir last No­vem­ber, and three De­moc­rats in the Sen­ate want to know why, lay­ing out their ques­tions in a let­ter to lead­ers of the com­pa­ny on Tues­day.

Sens. Jeanne Sha­heen (D-NH), Eliz­a­beth War­ren (D-MA) and Raphael Warnock (D-GA) sought more in­for­ma­tion on sup­ply con­straints and whether No­vo would con­sid­er pro­duc­ing Lev­emir un­til biosim­i­lars are avail­able. They gave No­vo un­til May 1 to re­spond to the ques­tions.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER